<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78793">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732146</url>
  </required_header>
  <id_info>
    <org_study_id>110111</org_study_id>
    <nct_id>NCT01732146</nct_id>
  </id_info>
  <brief_title>Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy</brief_title>
  <acronym>Neurepo</acronym>
  <official_title>Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelea in Term Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of high dose Erythropoietin to
      improve survival and neurologic outcome in asphyxiated term newborn undergoing cooling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic-ischemic encephalopathy remains the main cause of death or long term neurologic
      impairments in neonates. Yet, therapies for birth asphyxia are currently limited.
      Hypothermia when applied within 6 hours after birth demonstrate partial improvement in
      outcome of newborns specially those with moderate form. Erythropoietin and its receptors are
      upregulated after brain injury in ischemic conditions. Systemically administered
      erythropoietin is neuroprotective in animal models of birth asphyxia. To date, one study
      demonstrate improvement neurologic outcome in asphyxiated term newborn under erythropoietin
      treatment but no reports evaluating beneficial of erythropoietin associated with cooling.
      This is a large randomised controlled trial to evaluate the efficacy of high dose
      erythropoietin on outcome at two years of asphyxiated term newborns undergoing cooling.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival without neurologic sequelea</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>Within 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of dead patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of moderate and severe sequelae</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mental Developmental index (Brunet Lezine Test), motor, visual and hearing impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspect of brain lesions on MRI</measure>
    <time_frame>at day 6 and day 12 after birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain MRI performed between day 6 and day 12 after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of treatment</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Erythropoietin beta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 to 1500 U/kg/dose X 3 every 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.2 ml saline solution X 3 given every 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin Beta</intervention_name>
    <description>erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery</description>
    <arm_group_label>Erythropoietin beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.2 ml saline solution X 3 given every 24 hours with the first dose within 12 hours of delivery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term or near-term newborn  (&gt; = 36 weeks gestational age)

          -  Moderate to severe encephalopathy

          -  undergoing moderate controlled hypothermia started within 6 hours after delivery

          -  Beneficiary of social security plan

          -  Informed consent parental authority

        Exclusion Criteria:

          -  Impossibility of getting controlled hypothermia before H6

          -  Infant older than 12 hours of age

          -  Chromosomal or significant congenital abnormality

          -  Predictable surgery in the first 3 days of life

          -  Uncontrolled collapse

          -  Haemorrhagic syndrome unchecked

          -  Head trauma with or without skull fracture
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana Patkai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cochin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliana Patkai, MD, PhD</last_name>
    <phone>+ 33 1 58 41 54 12</phone>
    <email>juliana.patkai@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>: +33 1 71 19 64 94</phone>
    <email>laurence.lecomte@nck.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Patkai, PhD</last_name>
      <phone>+ 33 1 58 41 54 12</phone>
      <email>Juliana.patkai@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Juliana Patkai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G, Blomgren K, Wang X. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009 Aug;124(2):e218-26. Epub 2009 Jul 27.</citation>
    <PMID>19651565</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>August 2, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxic Ischemic Encephalopathy</keyword>
  <keyword>Term neonate</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>erythropoietin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
